Skip to main content
. 2020 Jul 20;21(14):5137. doi: 10.3390/ijms21145137

Figure 1.

Figure 1

The effects of ruxolitinib treatment on the human dermal papilla cells (hDPCs) viability. Cell viability was not significantly affected by various concentrations of ruxolitinib treatment. The data represent the means ± SEM, n = 4, statistically significant at * p < 0.05, ** p < 0.01, *** p < 0.001, compared with the control.